NCT07123662

γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

A Clinical Study on the Safety and Efficacy of γδ T Cells in Preventing Relapse After Allogeneic Transplantation in High-risk Acute Myeloid Leukemia Patients

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Guangzhou Bio-gene Technology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study

Detailed description

This study is a prospective, single-center, two-arm, single-blind randomized controlled clinical trial to evaluate the safety and efficacy of γδ T cell infusion in preventing recurrence in patients with high-risk AML after allogeneic transplantation.

Conditions

• Leukemia
• Myeloid
• Acute

Interventions

Type	Name	Description
BIOLOGICAL	Gamma-Delta T cell injection	Experimental group: Peripheral intravenous infusion of γδ T cells
OTHER	Standard prophylactic treatment	Standard prophylactic treatment

Timeline

• Start date: 2025-09-01
• Primary completion: 2028-05-30
• Completion: 2028-05-30
• First posted: 2025-08-14
• Last updated: 2025-08-14